FDA Approves Merck's WINREVAIR, a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension
WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone
Source: dicardiology.com
